EA030741B1 - Адъювантное соединение - Google Patents

Адъювантное соединение Download PDF

Info

Publication number
EA030741B1
EA030741B1 EA201490709A EA201490709A EA030741B1 EA 030741 B1 EA030741 B1 EA 030741B1 EA 201490709 A EA201490709 A EA 201490709A EA 201490709 A EA201490709 A EA 201490709A EA 030741 B1 EA030741 B1 EA 030741B1
Authority
EA
Eurasian Patent Office
Prior art keywords
leu
ser
lys
antigen
glu
Prior art date
Application number
EA201490709A
Other languages
English (en)
Russian (ru)
Other versions
EA201490709A1 (ru
Inventor
Фердинанд Антониус Осендорп
Корнелис Йоханнес Мария Мелиф
Селина Кан
Дмитрий Викторович Филиппов
Гейсберт Ари Ван Дер Марел
Original Assignee
АйЭсЭй ФАРМАСЬЮТИКАЛЗ Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by АйЭсЭй ФАРМАСЬЮТИКАЛЗ Б.В. filed Critical АйЭсЭй ФАРМАСЬЮТИКАЛЗ Б.В.
Publication of EA201490709A1 publication Critical patent/EA201490709A1/ru
Publication of EA030741B1 publication Critical patent/EA030741B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
EA201490709A 2011-10-05 2012-10-04 Адъювантное соединение EA030741B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161543510P 2011-10-05 2011-10-05
NL2007536A NL2007536C2 (en) 2011-10-05 2011-10-05 Adjuvant compound.
US201261615566P 2012-03-26 2012-03-26
PCT/NL2012/050694 WO2013051936A1 (en) 2011-10-05 2012-10-04 Adjuvant compound

Publications (2)

Publication Number Publication Date
EA201490709A1 EA201490709A1 (ru) 2014-09-30
EA030741B1 true EA030741B1 (ru) 2018-09-28

Family

ID=48043964

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490709A EA030741B1 (ru) 2011-10-05 2012-10-04 Адъювантное соединение

Country Status (16)

Country Link
US (2) US9314521B2 (enExample)
EP (1) EP2763697B9 (enExample)
JP (1) JP6099210B2 (enExample)
KR (1) KR102053699B1 (enExample)
CN (1) CN104244976B (enExample)
AU (1) AU2012319265B2 (enExample)
BR (1) BR112014008214B1 (enExample)
CA (1) CA2886631C (enExample)
EA (1) EA030741B1 (enExample)
ES (1) ES2952644T3 (enExample)
IL (1) IL231951B (enExample)
IN (1) IN2014DN03325A (enExample)
MX (1) MX356028B (enExample)
NL (1) NL2007536C2 (enExample)
SG (1) SG11201401291XA (enExample)
WO (1) WO2013051936A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1219477A1 (zh) 2013-03-21 2017-04-07 Sanofi-Aventis Deutschland Gmbh 合成含有乙内酰脲的肽产物
EP2976325B1 (en) 2013-03-21 2017-03-01 Sanofi-Aventis Deutschland GmbH Synthesis of cyclic imide containing peptide products
WO2014207708A2 (en) 2013-06-28 2014-12-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
WO2015187009A1 (en) 2014-06-02 2015-12-10 Isa Pharmaceuticals B.V. Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection
CN107250103A (zh) 2014-12-23 2017-10-13 玛格丽特·安妮·布林布尔 氨基酸缀合物和肽缀合物以及其用途
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
IL298653A (en) 2015-12-11 2023-01-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides for use in immunotherapy against several types of cancer
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
CA3027459A1 (en) 2016-06-20 2017-12-28 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
IL302880A (en) 2017-04-04 2023-07-01 Avidea Tech Inc Peptide-based ingredients, production methods, and their uses for inducing an immune response
WO2019122050A1 (en) 2017-12-22 2019-06-27 Isa Pharmaceuticals B.V. Methods of immunization
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
KR20220143812A (ko) 2019-12-07 2022-10-25 아이에스에이 파마슈티컬즈 비.브이. B형 간염 바이러스와 관련된 질병의 치료
EP4100051A2 (en) 2020-02-07 2022-12-14 ISA Pharmaceuticals B.V. Treatment of hpv-related diseases
EP4138876A1 (en) 2020-04-23 2023-03-01 ISA Pharmaceuticals B.V. Immunization against sars-cov-related diseases
WO2023285412A1 (en) 2021-07-12 2023-01-19 Isa Pharmaceuticals B.V. Improved substance quantification in complex mixtures
WO2024068636A1 (en) 2022-09-27 2024-04-04 Isa Pharmaceuticals B.V. Adjuvanted immunogenic peptides for intradermal administration
EP4601685A1 (en) 2022-10-13 2025-08-20 Isabella Pharma B.V. Modified long peptides suitable for use in immunisation
WO2024149888A1 (en) 2023-01-12 2024-07-18 Isa Pharmaceuticals B.V. Improved lipopeptide quantification
WO2025008085A1 (en) 2023-07-05 2025-01-09 Isa Pharmaceuticals B.V. Immunotherapy for the treatment of prame-expressing cancers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431327A1 (de) * 1989-11-10 1991-06-12 Hoechst Aktiengesellschaft Synthetische Vakzine zur spezifischen Induktion zytotoxischer T-Lymphozyten

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485094D1 (de) * 1983-01-25 1991-10-31 Ciba Geigy Ag Neue peptidderivate.
US6024964A (en) * 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
WO2001000828A2 (en) 1999-06-30 2001-01-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6504010B1 (en) 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6686447B1 (en) 1999-06-30 2004-02-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
NL1012739C2 (nl) 1999-07-29 2001-01-30 Maasland Nv Voerinrichting, in het bijzonder voor het verstrekken van krachtvoer.
ES2519043T3 (es) 2000-12-08 2014-11-06 Academisch Ziekenhuis Leiden Péptidos largos de 22-45 residuos de aminoácidos que inducen y/o mejoran las respuestas inmunológicas específicas para antígenos
MXNL04000056A (es) 2004-06-30 2006-01-11 Mario Alberto Aguilera Rico Sistema de construccion terra acero.
US7943140B2 (en) * 2006-08-14 2011-05-17 Thymon, Llc Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
CN101687022B (zh) 2007-03-26 2016-09-07 莱顿大学医学中心附属莱顿教学医院 Prame衍生的肽以及包括该肽的免疫原组合物
WO2008147187A1 (en) 2007-05-31 2008-12-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
WO2008147186A1 (en) 2007-05-31 2008-12-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc P53 peptide vaccine
KR100900837B1 (ko) * 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물
EA023725B1 (ru) * 2010-03-23 2016-07-29 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431327A1 (de) * 1989-11-10 1991-06-12 Hoechst Aktiengesellschaft Synthetische Vakzine zur spezifischen Induktion zytotoxischer T-Lymphozyten

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOYLE PETER M; TOTH ISTVAN: "Self-adjuvanting lipopeptide vaccines.", CURRENT MEDICINAL CHEMISTRY, BENTHAM, NL, vol. 15, no. 5, 1 January 2008 (2008-01-01), NL, pages 506 - 516, XP009104575, ISSN: 0929-8673, DOI: 10.2174/092986708783503249 *
TSUNEAKI HIDA, KOZO HAYASHI, KOICHI YUKISHIGE, SEIICHI TANIDA, NORIAKI KAWAMURA, SETSUO HARADA: "Synthesis and Biological Activities of TAN-1511 Analogues.", THE JOURNAL OF ANTIBIOTICS, vol. 48, no. 7, 1 January 1995 (1995-01-01), pages 589 - 603, XP055023889, ISSN: 00218820, DOI: 10.7164/antibiotics.48.589 *

Also Published As

Publication number Publication date
EA201490709A1 (ru) 2014-09-30
EP2763697C0 (en) 2023-06-07
NL2007536C2 (en) 2013-04-08
IL231951B (en) 2019-08-29
KR20140093673A (ko) 2014-07-28
NZ623869A (en) 2015-11-27
WO2013051936A1 (en) 2013-04-11
CN104244976B (zh) 2017-05-31
JP6099210B2 (ja) 2017-03-22
KR102053699B1 (ko) 2019-12-09
EP2763697B1 (en) 2023-06-07
US9770506B2 (en) 2017-09-26
US20160250325A1 (en) 2016-09-01
AU2012319265B2 (en) 2016-10-13
SG11201401291XA (en) 2014-05-29
IN2014DN03325A (enExample) 2015-06-26
WO2013051936A9 (en) 2013-09-12
CA2886631C (en) 2019-06-11
CA2886631A1 (en) 2013-04-11
IL231951A0 (en) 2014-05-28
AU2012319265A1 (en) 2014-05-22
BR112014008214B1 (pt) 2022-07-05
EP2763697B8 (en) 2023-07-12
BR112014008214A2 (pt) 2017-06-13
EP2763697A1 (en) 2014-08-13
ES2952644T3 (es) 2023-11-02
US20150104473A1 (en) 2015-04-16
CN104244976A (zh) 2014-12-24
MX2014004114A (es) 2014-10-17
JP2014530808A (ja) 2014-11-20
MX356028B (es) 2018-05-09
EP2763697B9 (en) 2023-10-04
US9314521B2 (en) 2016-04-19

Similar Documents

Publication Publication Date Title
US9770506B2 (en) Adjuvant compound
JP7190528B2 (ja) 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びtlrペプチドアゴニストを含む新規複合体
JP7181880B2 (ja) 免疫療法のためのコア/シェル構造プラットホーム
CN104736553B (zh) 细胞穿透肽
JP5230579B2 (ja) 癌抑制遺伝子wt1の産物に基づく癌抗原
EP2247306B1 (en) Immunogenic control of tumours and tumour cells
US12016918B2 (en) Peptide-containing adjuvant compounds having peg spacers
WO2021123232A1 (en) Nucleic acid vaccination using neo-epitope encoding constructs
NZ623869B2 (en) Improved pam3cys-like lipopeptide adjuvant compound
KR20250151414A (ko) 텔로머라제 역전사효소(tert) 양성 종양에 대한 백신

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ